ABCC tool
50+
Downloads
Everyone
info
About this app
The "ABCC Alto Adige" study is a randomized intervention study, i.e. usual treatment
is extended to a portion of patients, while another portion of patients receives treatment
unchanged standard.
The study analyzes a tool called Assessment of Burden of Chronic Conditions (ABCC),
designed to comprehensively assess and report the burden and perception of chronic disease
in patients affected by them. This ABCC tool is already used successfully in general practice
in Holland.
The study will then be conducted on patients suffering from the aforementioned chronic diseases, cared for in the
General (Family) Medicine clinics in the South Tyrol area. Participants will be
divided into two groups. A group will be followed with the ABCC tool, which will allow self-evaluation
initially give the patient his state of health, commented on and evaluated with the results obtained for the treatment immediately afterwards during the medical examination, with his family doctor; while the other group will receive conventional care and treatment.
The main objective of the study is to discover how the perceived quality of life can change
by patients, after 18 months of using the innovative ABCC tool. Therefore, we will try to understand whether the ABCC tool can lead to an improvement in the quality of life
behavior and self-management of the chronic diseases the patient suffers from, all of this
the Healthcare System would also improve in management terms. Based on the
usage data, a cost-effectiveness analysis will be conducted to verify whether this type of
treatment also makes economic sense.
What are the risks?
There are no specific risks associated with participation in this study. No one is intended to be used
experimental drug. However, you will be informed promptly if they become available
information that may influence your willingness to continue participation.
Will my data remain anonymous?
All information related to your participation in this Study will be treated accordingly
strictly confidential in accordance with the rules of Good Clinical Practice (Legislative Decree 211/2003), as well as
to those relating to the protection and processing of personal data, pursuant to the Regulation
European no. 679/2016, so-called GDPR, and the Italian legislation currently in force regarding
Privacy.
The personal data will be associated with a code, from which it will be impossible to trace your identity:
only the investigating doctor will be able to link the code to your name.
The investigator doctor who will follow you in the study in question, the persons in charge of the
monitoring of the Study and the Regulatory Authorities may have access to your personal data,
in compliance with and with the limitations provided for by European Regulation no. 679/2016, by Legislative Decree 196/2003,
as amended by Legislative Decree 101/2018, and by the Guidelines of the Data Protection Guarantor
personal (resolution no. 52 of 07/24/2008 and subsequent amendments and additions). The assigned staff
the Firm is however obliged to maintain, in any case, the confidentiality of such information.
We ask you to refer to the Information Note on the processing of personal data, which will be provided to you
delivered together with this Information Sheet, to fully understand your rights in
matter.
Who can I contact for further information?
If you have any questions or would like further information, do not hesitate to contact your doctor
investigator responsible for the study and/or who proposed it to you
participation in this observational study.
Dr. Christian J. Wiedermann
Version no. 2 of 8.7.2023
is extended to a portion of patients, while another portion of patients receives treatment
unchanged standard.
The study analyzes a tool called Assessment of Burden of Chronic Conditions (ABCC),
designed to comprehensively assess and report the burden and perception of chronic disease
in patients affected by them. This ABCC tool is already used successfully in general practice
in Holland.
The study will then be conducted on patients suffering from the aforementioned chronic diseases, cared for in the
General (Family) Medicine clinics in the South Tyrol area. Participants will be
divided into two groups. A group will be followed with the ABCC tool, which will allow self-evaluation
initially give the patient his state of health, commented on and evaluated with the results obtained for the treatment immediately afterwards during the medical examination, with his family doctor; while the other group will receive conventional care and treatment.
The main objective of the study is to discover how the perceived quality of life can change
by patients, after 18 months of using the innovative ABCC tool. Therefore, we will try to understand whether the ABCC tool can lead to an improvement in the quality of life
behavior and self-management of the chronic diseases the patient suffers from, all of this
the Healthcare System would also improve in management terms. Based on the
usage data, a cost-effectiveness analysis will be conducted to verify whether this type of
treatment also makes economic sense.
What are the risks?
There are no specific risks associated with participation in this study. No one is intended to be used
experimental drug. However, you will be informed promptly if they become available
information that may influence your willingness to continue participation.
Will my data remain anonymous?
All information related to your participation in this Study will be treated accordingly
strictly confidential in accordance with the rules of Good Clinical Practice (Legislative Decree 211/2003), as well as
to those relating to the protection and processing of personal data, pursuant to the Regulation
European no. 679/2016, so-called GDPR, and the Italian legislation currently in force regarding
Privacy.
The personal data will be associated with a code, from which it will be impossible to trace your identity:
only the investigating doctor will be able to link the code to your name.
The investigator doctor who will follow you in the study in question, the persons in charge of the
monitoring of the Study and the Regulatory Authorities may have access to your personal data,
in compliance with and with the limitations provided for by European Regulation no. 679/2016, by Legislative Decree 196/2003,
as amended by Legislative Decree 101/2018, and by the Guidelines of the Data Protection Guarantor
personal (resolution no. 52 of 07/24/2008 and subsequent amendments and additions). The assigned staff
the Firm is however obliged to maintain, in any case, the confidentiality of such information.
We ask you to refer to the Information Note on the processing of personal data, which will be provided to you
delivered together with this Information Sheet, to fully understand your rights in
matter.
Who can I contact for further information?
If you have any questions or would like further information, do not hesitate to contact your doctor
investigator responsible for the study and/or who proposed it to you
participation in this observational study.
Dr. Christian J. Wiedermann
Version no. 2 of 8.7.2023
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
This app may collect these data types
Personal info, Health and fitness and 2 others
Data is encrypted in transit
You can request that data be deleted
What’s new
Improvements to the user experience
App support
phone
Phone number
+31162520964
About the developer
Curavista B.V.
anton.kool@curavista.nl
Oeverkruid 13
4941 VV Raamsdonksveer
Netherlands
+31 6 55120654
